1. Gallo RC, Salahuddin SZ, Popovic M, et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science. 1984; 224: 500 - 503.

2. Popovic M, Sarngadharan MG, Read E, et al. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science. 1984; 224: 497 - 500.

3. Бартлетт Дж., Редфилд Р., Фам П., Мазус А.И. Клинические аспекты ВИЧ-инфекции. Российское издание 2013. М.: ГРАНАТ; 2013: 696.

4. Либман Г., Макадон Х.Дж. ВИЧ-инфекция. Пер. с англ. Мазус А.И., Бессараб Т.П., ред. М.: ГЭОТАР-Медиа; 2013: 560.

5. Покровский В.В., ред. ВИЧ-инфекция и СПИД. Национальное руководство. М.: ГЭОТАР-Медиа; 2020: 696.

6. Беляков Н.А., Рассохин В.В., Розенталь В.В., Огурцова С.В., Степанова Е.В., Мельникова Т.Н., Курганова Т.Ю., Азовцева О.В., Симакина О.Е., Тотолян А.А. Эпидемиология ВИЧ-инфекции. Место мониторинга, научных и дозорных наблюдений, моделирования и прогнозирования обстановки. ВИЧ-инфекция и иммуносупрессии, 2019, Том 11, N 2.

7. Клиническая классификация ВИЧ-инфекции. Приложение к Инструкции по заполнению годовой формы государственного федерального статистического наблюдения N 61 "Сведения о контингентах больных ВИЧ-инфекцией", утвержденной Приказом Минздравсоцразвития России от 17.03.2006 г. N 166.

8. Барлетт Д., Галлант Д. Фам П. Клинические аспекты ВИЧ-инфекции. 2009 - 2010. М.: Р. Валент, 2010. 490 с.

9. Покровский В.В., ред. ВИЧ-инфекция и СПИД. Клинические рекомендации. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа, 2010. 186 с.

10. Покровский В.В., ред. ВИЧ-инфекция и СПИД. Национальное руководство. М.: ГЭОТАР-Медиа, 2013. 608 с.

11. Покровский В.В., Юрин О.Г., Кравченко А.В., Беляева В.В., Ермак Т.Н., Канестри В.Г., Шахгильдян В.И., Козырина Н.В., Буравцова В.В., Нарсия Р.С., Покровская А.В., Ефремова О.С., Коннов В.В., Куимова У.А., Попова А.А., Хохлова О.Н., Воронин Е.Е., Афонина Л.Ю., Васильева И.А., Зимина В.Н. Национальные рекомендации по диспансерному наблюдению и лечению ВИЧ-инфекцией. Клинический протокол. Эпидемиология и инфекционные болезни. Актуальные вопросы 2016; 6 (приложение). 120 с.

12. Постановление Главного Государственного санитарного врача РФ от 21 июля 2016 года N 95 "О внесении изменений в СП 3.1.5.2826-10 Профилактика ВИЧ-инфекции."

13. Покровский В.В., Ладная Н.Н., Соколова Е.В., Буравцова Е.В. ВИЧ-инфекция. Информационный бюллетень N 43. - М: 2018, - 55 с.

14. Przybyla S. M. et al. Meta-analysis of alcohol and serodiscordant condomless sex among people living with HIV//Archives of sexual behavior. - 2018. - Т. 47. - N. 5. - С. 1351 - 1366.

15. Smolak A. A meta-analysis and systematic review of HIV risk behavior among fishermen//AIDS care. - 2014. - Т. 26. - N. 3. - С. 282 - 291.

16. Wang Z. D. et al. Prevalence and burden of Toxoplasma gondii infection in HIV-infected people: a systematic review and meta-analysis//The Lancet HIV. - 2017. - Т. 4. - N. 4. - С. e177 - e188.

17. Dianatinasab M. et al. Prevalence of tuberculosis in HIV-positive prisoners: a systematic review and meta-analysis//AIDS reviews. - 2018. - Т. 20. - N. 2. - С. 114 - 124.

18. Kouyoumjian S. P. et al. Global population-level association between herpes simplex virus 2 prevalence and HIV prevalence//AIDS (London, England). - 2018. - Т. 32. - N. 10. - С. 1343.

19. Lan C. W. et al. Prevalence of alcohol use, sexual risk behavior, and HIV among Russians in high-risk settings: a systematic review and meta-analysis//International journal of behavioral medicine. - 2017. - Т. 24. - N. 2. - С. 180 - 190.

20. Qiang W. E. I. et al. Circumcision status and risk of HIV acquisition during heterosexual intercourse for both males and females: A meta-analysis//PLoS One. - 2015. - Т. 10. - N. 5. - С. e0125436. Svensson P. et al. A meta-analysis and systematic literat.

21. Svensson P. et al. A meta-analysis and systematic literature review of factors associated with sexual risk-taking during international travel//Travel medicine and infectious disease. - 2018. - Т. 24. - С. 65 - 88.

22. Platt L. et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis//The Lancet infectious diseases. - 2016. - Т. 16. - N. 7. - С. 797 - 808.

23. Low A. et al. Incidence of opportunistic infections and the impact of antiretroviral therapy among HIV-infected adults in low-and middle-income countries: a systematic review and meta-analysis//Clinical infectious diseases. - 2016. - Т. 62. - N. 12. - С.

24. Sabbagh P. et al. The global and regional prevalence, burden, and risk factors for methicillin-resistant Staphylococcus aureus colonization in HIV-infected people: a systematic review and meta-analysis//American Journal of Infection Control. - 2019. - Т.

25. Hamada Y. et al. Sensitivity and specificity of WHO's recommended four-symptom screening rule for tuberculosis in people living with HIV: a systematic review and meta-analysis//The Lancet HIV. - 2018. - Т. 5. - N. 9. - С. e515 - e523

26. Losa J. et al. Opt-out screening strategy for HIV infection among patients attending emergency departments: systematic review and meta-analysis. - 2016.

27. Gebrezgi, M. T., Mauck, D. E., Sheehan, D. M., Fennie, K. P., Cyrus, E., Degarege, A., & Trepka, M. J. (2019). Acceptance of Opt-Out HIV Screening in Outpatient Settings in the United States: A Systematic Review and Meta-Analysis. Public Health Reports, 0.

28. Smallwood M. et al. Evaluation of a rapid point of care test for detecting acute and established HIV infection, and examining the role of study quality on diagnostic accuracy: a Bayesian meta-analysis//PloS one. - 2016. - Т. 11. - N. 2. - С. e0149592.

29. Tan W. S. et al. Sensitivity of HIV rapid tests compared with fourth-generation enzyme immunoassays or HIV RNA tests//Aids. - 2016. - Т. 30. - N. 12. - С. 1951 - 1960.

30. R. C. et al. Evaluation of Enzyme Immunoassay (EIA), Immunoblot and HIV RNA Polymerase Chain Reaction Test Results in the Diagnosis of Human Immunodeficiency Virus (HIV) Infection//Mikrobiyoloji bulteni. - 2019. - Т. 53. - N. 4. - С. 401 - 407.

31. Wu S. et al. Prevalence of HIV Indeterminate Western Blot Tests and Follow-up of HIV Antibody Sero-Conversion in Southeastern China//Virologica Sinica. - 2019. - Т. 34. - N. 4. - С. 358 - 366

32. Babiker A. et al. Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: A meta-analysis//AIDS Research and Human Retroviruses. - 2000. - Т. 16. - N. 12. - С. 1123 - 1133.

33. Fox M., McCarthy O., Over M. A novel approach to accounting for loss to follow-up when estimating the relationship between CD4 count at ART initiation and mortality//PLoS One. - 2013. - Т. 8. - N. 7. - С. e69300.

34. Baillargeon J., Grady J., Borucki M. J. Immunological predictors of HIV-related survival//International journal of STD & AIDS. - 1999. - Т. 10. - N. 7. - С. 467 - 470.

35. Kebede M., Zegeye D. T., Zeleke B. M. Predicting CD4 count changes among patients on antiretroviral treatment: Application of data mining techniques//Computer methods and programs in biomedicine. - 2017. - Т. 152. - С. 149 - 157.

36. Stephan C. et al. Impact of baseline HIV-1 RNA levels on initial highly active antiretroviral therapy outcome: a meta-analysis of 12,370 patients in 21 clinical trials//HIV medicine. - 2013. - Т. 14. - N. 5. - С. 284 - 292.

37. EACS Guidelines Version 10, 2019. https://www.eacsociety.org/files/2019_guidelines-10.0_final.pdf

38. Murray JS, Elashoff MR, Iacono-Connors LC, Cvetkovich TA, Struble KA. The use of plasma HIV NA as a study endpoint in efficacy trials of antiretroviral drugs. AIDS. May 7 1999; 13(7): 797 - 804

39. Marschner IC, Collier AC, Coombs RW, et al. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis. Jan 1998; 177(1): 40 - 47.

40. Laprise C, de Pokomandy A, Baril JG, Dufresne S, Trottier H. Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation. Clin Infect Dis. Nov 2013; 57(10): 1489 - 1496.

41. Wankah P. N., Tagny C. T., Mbanya D. N. S. Profile of blood cell abnormalities among antiretroviral therapy HIV patients attending the Yaounde University Teaching Hospital, Cameroon//BMC hematology. - 2014. - Т. 14. - N. 1. - С. 15.

42. Fellay, J., Ledergerber, B., Bernasconi, E., Furrer, H., Battegay, M., Hirschel, B., ... Telenti, A. (2001). Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. The Lancet, 358(9290), 1322 - 1327. doi: 10.1016/.

43. Mapanga W. et al. Prevention of cervical cancer in HIV-seropositive women from developing countries through cervical cancer screening: a systematic review//Systematic reviews. - 2018. - Т. 7. - N. 1. - С. 198.

44. Liu G. et al. HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer//Aids. - 2018. - Т. 32. - N. 6. - С. 795 - 808.

45. Ucciferri C. et al. Prevalence of anal, oral, penile and urethral human papillomavirus in HIV infected and HIV uninfected men who have sex with men//Journal of medical virology. - 2018. - Т. 90. - N. 2. - С. 358 - 366.

46. Clifford G. M., Tully S., Franceschi S. Carcinogenicity of human papillomavirus (HPV) types in HIV-positive women: a meta-analysis from HPV infection to cervical cancer//Clinical Infectious Diseases. - 2017. - Т. 64. - N. 9. - С. 1228 - 1235.

47. King E. M. et al. Oral human papillomavirus infection in men who have sex with men: a systematic review and meta-analysis//PloS one. - 2016. - Т. 11. - N. 7. - С. e0157976.

48. Islam F. M. et al. Relative risk of renal disease among people living with HIV: a systematic review and meta-analysis//BMC public health. - 2012. - Т. 12. - N. 1. - С. 234.

49. Ekrikpo U. E. et al. Chronic kidney disease in the global adult HIV-infected population: a systematic review and meta-analysis//PLoS One. - 2018. - Т. 13. - N. 4. - С. e0195443.

50. Barraclough K. et al. A comparison of the predictive performance of different methods of kidney function estimation in a well-characterized HIV-infected population//Nephron Clinical Practice. - 2009. - Т. 111. - N. 1. - С. c39 - c48.

51. Ford N. et al. CD4 cell count threshold for cryptococcal antigen screening of HIV-infected individuals: a systematic review and meta-analysis//Clinical Infectious Diseases. - 2018. - Т. 66. - N. suppl_2. - С. S152 - S159.

52. Diedrich C. R., O'Hern J., Wilkinson R. J. HIV-1 and the Mycobacterium tuberculosis granuloma: A systematic review and meta-analysis//Tuberculosis. - 2016. - Т. 98. - С. 62 - 76.

53. Khademi F. et al. Bacterial co-infections in HIV/AIDS-positive subjects: A systematic review and meta-analysis//Folia medica. - 2018. - Т. 60. - N. 3. - С. 339 - 350.

54. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV-infection.

55. Recommendation for the public health approach. WHO, 2nd edition, 2016. 480p. http://www.who.int/hiv.

56. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Developed by the panel on clinical practices for treatment of HIV infection convened by the Department of Health and Human Services (DHHS). July 14, 2016.

57. HIV 2015/2016. Edited Hoffmann C., Rockstroh J.K. Medizin Fokus Verlag, Hamburg, 2015. 776 с.

58. Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. World Health Organization, 2016 Update. http://www.who.int/hiv

59. Лисицина З.Н., Дмитриевская К.А., Коробан Н.В., Кондрашова Т.В. Иммунные тесты и диагностика острой стадии ВИЧ-инфекции. ВИЧ-инфекция и иммуносупрессии, 2017 г., том 9, N 2.

60. Рекомендации по диагностике и лечению взрослых больных с гепатитом C. МАСОИ. Москва, 2017. 69 с.

61. Bystryak S., Ossina N. A rapid ultrasound particle agglutination method for HIV antibody detection: Comparison with conventional rapid HIV tests//Journal of virological methods. - 2017. - Т. 249. - С. 38 - 47.

62. Scott RK, Crochet S, Huang CC. Universal rapid human immunodeficiency virus screening at delivery: a costeffectiveness analysis. Infec Dis Obstet Gynecol. 2018; 2018: 6024698. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29731602.

63. Владимиров К.Б., Марфина Г.Ю., Иванов А.К. Роль флюорографического обследования в выявлении туберкулеза у больных с ВИЧ-инфекцией в пенитенциарных учреждениях//ВИЧ-инфекция и иммуносупрессии. - 2015. - Т. 7. - N. 2. - С. 69 - 76.

64. Nduka C. U. et al. Evidence of increased blood pressure and hypertension risk among people living with HIV on antiretroviral therapy: a systematic review with meta-analysis//Journal of Human Hypertension. - 2016. - Т. 30. - N. 6. - С. 355 - 362.

65. Patel N. et al. Frequency of electrocardiogram testing among HIV-infected patients at risk for medication-induced QTc prolongation//HIV medicine. - 2013. - Т. 14. - N. 8. - С. 463 - 471.

66. Xu Y., Chen X., Wang K. Global prevalence of hypertension among people living with HIV: a systematic review and meta-analysis//Journal of the American Society of Hypertension. - 2017. - Т. 11. - N. 8. - С. 530 - 540.

67. Van Hoving D. J. et al. Abdominal ultrasound for diagnosing abdominal tuberculosis or disseminated tuberculosis with abdominal involvement in HIV-positive individuals//Cochrane Database of Systematic Reviews. - 2019. - N. 9.

68. N'Gbesso R. D. et al. Renal insufficiency: comparison of ultrasound and laboratory profiles in HIV-negative and HIV-positive patients//Cahiers et de recherches francophones/. - 2005. - Т. 15. - N. 3. - С. 183 - 187.

69. Ulu U. O., Agbaji O., Agwu K. K. Sonographic characterization of renal pathologies in HIV/AIDS in Plateau State, Nigeria//Nigerian journal of medicine: journal of the National Association of Resident Doctors of Nigeria. - 2012. - Т. 21. - N. 2. - С. 160-.

70. Granata A. et al. Ultrasound assessment in renal infections//Giornale italiano di nefrologia: organo ufficiale della Societa italiana di nefrologia. - 2012. - Т. 29. - С. S47 - 57

71. Krikke M. et al. Cardiovascular risk prediction in HIV-infected patients: comparing the Framingham, atherosclerotic cardiovascular disease risk score (ASCVD), Systematic Coronary Risk Evaluation for the Netherlands (SCORE NL) and Data Collection on Adver. 2016.

72. Gupta M. et al. Biomarkers and electrocardiographic evidence of myocardial ischemia in patients with human immunodeficiency virus infection//The American journal of cardiology. - 2013. - Т. 111. - N. 5. - С. 760 - 764.

73. Ssentongo P. Prevalence and incidence of new-onset seizures and epilepsy in patients with human immunodeficiency virus (HIV): Systematic review and meta-analysis//Epilepsy & Behavior. - 2019. - Т. 93. - С. 49 - 55.

74. O'connor E. E., Zeffiro T. A., Zeffiro T. A. Brain structural changes following HIV infection: meta-analysis//American Journal of Neuroradiology. - 2018. - Т. 39. - N. 1. - С. 54 - 62.

75. Sin N. L., DiMatteo M. R. Depression treatment enhances adherence to antiretroviral therapy: a meta-analysis//Annals of Behavioral Medicine. - 2014. - Т. 47. - N. 3. - С. 259 - 269.

76. Luo Z. et al. Lifetime prevalence of suicidal ideation among men who have sex with men: a meta-analysis//BMC psychiatry. - 2017. - Т. 17. - N. 1. - С. 1 - 9.

77. Gandhi M, Aweeka F, Greenblatt RM, Blaschke TF. Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol. 2004; 44: 499 - 523.

78. Ofotokun I, Chuck SK, Hitti JE. Antiretroviral pharmacokinetic profile: a review of sex differences. Gend Med. 2007; 4(2): 106 - 119.

79. Ford N, Mofenson L, Shubber Z, et al. Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS. 2014; 28 Suppl 2: S123 - 131.

80. Zhang J, Chung E, Yones C, et al. The effect of atazanavir/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women. Antivir Ther. 2011; 16(2): 157 - 164.

81. Vogler MA, Patterson K, Kamemoto L, et al. Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188. J Acquir Immune Defic Syndr. 2010; 55(4): 473 - 482.

82. Stuart GS, Moses A, Corbett A, et al. Combined oral contraceptives and antiretroviral PK/PD in Malawian women: pharmacokinetics and pharmacodynamics of a combined oral contraceptive and a generic combined formulation antiretroviral in Malawi. J Acquir Immune Defic Syndr. 2011; 58(2): e40 - 43.

83. World Health Organization. Hormonal contraceptive methods for women at high risk of HIV and living with HIV: 2014 guidance statement. Geneva, Switzerland 2014.

84. Low A. et al. Incidence of opportunistic infections and the impact of antiretroviral therapy among HIV-infected adults in low-and middle-income countries: a systematic review and meta-analysis//Clinical infectious diseases. - 2016. - Т. 62. - N. 12. - С.

85. Ford N. et al. Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis//The lancet HIV. - 2015. - Т. 2. - N. 10. - С. E438 - e444.

86. Farahani M. et al. Prevalence and distribution of non-AIDS causes of death among HIV-infected individuals receiving antiretroviral therapy: a systematic review and meta-analysis//International journal of STD & AIDS. - 2017. - Т. 28. - N. 7. - С. 636 - 650.

87. Gutierrez J., Albuquerque A. L. A., Falzon L. HIV infection as vascular risk: a systematic review of the literature and meta-analysis//PloS one. - 2017. - Т. 12. - N. 5. - С. e0176686.

88. Poorolajal, J., Hooshmand, E., Mahjub, H., Esmailnasab, N., & Jenabi, E. (2016). Survival rate of AIDS disease and mortality in HIV-infected patients: a meta-analysis. Public Health, 139, 3 - 12. doi: 10.1016/j.puhe.2016.05.004.

89. Kanters, S., Park, J. J. H., Chan, K., Socias, M. E., Ford, N., Forrest, J. I.,... Mills, E. J. (2017). Interventions to improve adherence to antiretroviral therapy: a systematic review and network meta-analysis. The Lancet HIV, 4(1), e31 - e40. doi: 10.1016/.

90. Costa J. M. et al. Adherence to antiretroviral therapy for HIV/AIDS in Latin America and the Caribbean: Systematic review and meta analysis//Journal of the International AIDS Society. - 2018. - Т. 21. - N. 1. - С. e25066.

91. Bock P. et al. Baseline CD4 count and adherence to antiretroviral therapy: a systematic review and meta-analysis//JAIDS Journal of Acquired Immune Deficiency Syndromes. - 2016. - Т. 73. - N. 5. - С. 514 - 521

92. Song A. et al. From CD4-based initiation to treating all HIV-infected adults immediately: an evidence-based meta-analysis//Frontiers in immunology. - 2018. - Т. 9. - С. 212.

93. Siegfried N., Uthman O. A., Rutherford G. W. Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV infected, treatment naive adults//Cochrane Database of Systematic Reviews. - 2010. - N. 3.

94. Sturt A. S., Dokubo E. K., Sint T. T. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women//Cochrane Database of Systematic Reviews. - 2010. - N. 3.

95. Kourtis A. P. et al. Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis//Aids. - 2007. - Т. 21. - N. 5. - С. 607 - 615.

96. Uthman O. A. et al. Timing of initiation of antiretroviral therapy and adverse pregnancy outcomes: a systematic review and meta-analysis//The lancet HIV. - 2017. - Т. 4. - N. 1. - С. e21 - e30.

97. Gupta A. et al. Early mortality in adults initiating antiretroviral therapy (ART) in low-and middle-income countries (LMIC): a systematic review and meta-analysis//PloS one. - 2011. - Т. 6. - N. 12. - С. e28691.

98. Grinsztejn B. et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial//The Lancet infectious diseases. - 2014. - Т. 14. - N. 4. -.

99. A Framework for Analyzing the Determinants of Maternal Mortality - PubMed [Electronic resource]. URL: https://pubmed.ncbi.nlm.nih.gov/1557792/ (accessed: 25.06.2020).

100. Gout C. et al. Assisted Reproductive Technologies in HIV patients: a comprehensive review of indications, techniques and results//Gynecologie, obstetrique & fertilite. - 2011. - Т. 39. - N. 12. - С. 704 - 708.

101. Anglemyer A. et al. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane DB Syst Rev Issue 8//Art. No.: CD009153. DOI. - 2011. - Т. 10. - С. 14651858.

102. Ford N. et al. Benefits and risks of rapid initiation of antiretroviral therapy//AIDS (London, England). - 2018. - Т. 32. - N. 1. - С. 17.

103. Eshun Wilson I. et al. Early versus delayed antiretroviral treatment in HIV-positive people with cryptococcal meningitis//Cochrane Database of Systematic Reviews. - 2018. - N. 7.

104. Kourtis, A. P., Schmid, C. H., Jamieson, D. J., & Lau, J. (2007). Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. AIDS, 21(5), 607 - 615. doi: 10.1097/qad.0b013e32802ef2f6.

105. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015 (2016 interim update). http://www.bhiva.org/documents/Guidelines/Treatment/2016/treatment-guidelines-2016-interim-update.pdf.

106. Huldrych F. Genthard, Michael S. Saag, Constance A. Benson et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2016 Jul 12; 316(2): 191 - 210.

107. Recommendations of the International Antiviral Society-USA Panel. JAMA. 2016 Jul 12; 316(2): 191 - 210.

108. Рекомендации по лечению ВИЧ-инфекции и связанных с ней заболеваний, химиопрофилактике заражения ВИЧ/2019//Эпидемиология и инфекционные болезни. Актуальные вопросы. Прил. 2019; (4): 1 - 87.

109. Clay et al., Meta-Analysis of Studies Comparing Single and Multi-Tablet Fixed Dose Combination HIV Treatment Regimens, J Medicine (Baltimore). 2015 Oct. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4620781/

110. Cost-effectiveness of single- versus generic multiple-tablet regimens for treatment of HIV-1 infection in the United States/D. E. Sweet, F. L. Altice, C. J. Cohen, B. Vandewalle//PLoS ONE. - 2016. - Vol. 11(1). - 0147821.

111. Systematic reviews and meta-analyses informing the guidelines on the public health response to pretreatment HIV drug resistance. Web Annex 2. Geneva: World Health Organization; 2017 (http://www.who.int/hiv/topics/drugresistance/en, accessed 1 July 2017).

112. Uthman OA, Okwundu C, Gbenga K, Volmink J, Dowdy D, Zumla A, et al. Optimal Timing of antiretroviral therapy initiation for HIV-infected adults with newly diagnosed pulmonary tuberculosis: a systematic review and meta-analysis. Ann Intern Med. 2015; 163: 32 - 39

113. Aves T. et al. Antiretroviral resistance testing in HIV-positive people//Cochrane Database of Systematic Reviews. - 2018. - N. 11

114. Goh S. S. L. et al. Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors//Osteoporosis International. - 2018. - Т. 29. - N. 3. - С. 595 - 613.

115. Msoka T. F. et al. The effect of HIV infection, antiretroviral therapy on carotid intima-media thickness: A systematic review and meta-analysis//Life sciences. - 2019. - Т. 235. - С. 116851.

116. Al-Dakkak I. et al. The impact of specific HIV treatment-related adverse events on adherence to antiretroviral therapy: a systematic review and meta-analysis//AIDS care. - 2013. - Т. 25. - N. 4. - С. 400 - 414.

117. Bedimo R., Rosenblatt L., Myers J. Systematic review of renal and bone safety of the antiretroviral regimen efavirenz, emtricitabine, and tenofovir disoproxil fumarate in patients with HIV infection//HIV clinical trials. - 2016. - Т. 17. - N. 6. - С. 246.

118. Stainsby C. M. et al. Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA-B* 5701 Screening as a Risk-Mitigation Measure//Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. - 2019. - Т. 39. - N. 1. - С. 40 - 54

119. Tangamornsuksan W. et al. Association of HLA-B* 5701 genotypes and abacavir-induced hypersensitivity reaction: a systematic review and meta-analysis//Journal of Pharmacy & Pharmaceutical Sciences. - 2015. - Т. 18. - N. 1. - С. 68 - 76.

120. Mirgh S. P. et al. Refractory anemia in human immunodeficiency virus: Expect the unexpected//Journal of Family Medicine and Primary Care. - 2016. - Т. 5. - N. 3. - С. 727.

121. Fischl M. A. et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex//New England Journal of Medicine. - 1987. - Т. 317. - N. 4. - С. 185 - 191.

122. Liu P. T. et al. Study on the relationship between HIV drug resistance and CD4 (+) T cell counts among antiretroviral therapy patients with low viral load//Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]. - 2018. - Т. 52. - N. 3..

123. B., Zhang H., Levy D. N. NNRTI-induced HIV-1 protease-mediated cytotoxicity induces rapid death of CD4 T cells during productive infection and latency reversal//Retrovirology. - 2019. - Т. 16. - N. 1. - С. 17.

124. Cai J., Osikowicz M., Sebastiani G. Clinical significance of elevated liver transaminases in HIV-infected patients//Aids. - 2019. - Т. 33. - N. 8. - С. 1267 - 1282.

125. Lafaurie M. et al. Clinical features and risk factors for atazanavir (ATV)-associated urolithiasis: a case-control study//PLoS One. - 2014. - Т. 9. - N. 11. - С. e112836.

126. Taramasso L. et al. Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)//BMC infectious diseases.

127. Ramjan R. et al. Systematic review and meta-analysis: patient and programme impact of fixed-dose combination antiretroviral therapy//Tropical Medicine & International Health. - 2014. - Т. 19. - N. 5. - С. 501 - 513.

128. Snedecor S. J. et al. Burden of nonnucleoside reverse transcriptase inhibitor resistance in HIV-1-infected patients: a systematic review and meta-analysis//AIDS Research and Human Retroviruses. - 2014. - Т. 30. - N. 8. - С. 753 - 768.

129. Gupta R. K. et al. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis//The Lancet infectious diseases. - 2018. - Т. 18.

130. Panel on Clinical Practices for Treatment of HIV Infection et al. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents//African journal of medical practice. - 1998. - Т. 5. - N. 2. - С. 79. (Last updated December 18, 201.

131. Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med. 2009; 361(23): 2230 - 2240.

132. Post FA, Moyle GJ, Stellbrink HJ, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr. 2010; 55(1): 49 - 57.

133. Stellbrink, HJ, et al. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV 2019; Jun; 6(6): e364 - e372.

134. Mendes J. C. et al. Adverse reactions associated with first-line regimens in patient initiating antiretroviral therapy//European journal of clinical pharmacology. - 2018. - Т. 74. - N. 8. - С. 1077 - 1088.

135. Jiang J. et al. Dolutegravir (DTG, S/GSK1349572) combined with other ARTs is superior to RAL -or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trials//AIDS research and therapy. - 2016. - Т. 13. - N. 1. - С.

136. Кравченко А.В., Орлова-Морозова Е.А., Шимонова Т.Е., Козырев О.А., Нагимова Ф.И., Захарова Н.Г., и др. Эффективность и безопасность нового российского ненуклеозидного ингибитора обратной транскриптазы элсульфавирина в первой линии лечения ВИЧ-инфекции в комбинации с двумя нуклеозидными/нуклеотидными ингибиторами обратной транскриптазы - исследование 96 нед. Журнал инфектологии. 2018; 10(2): 76 - 82. DOI: 10.22625/2072-6732-2018-10-2-76-82(2А)

137. Оценка безопасности, переносимости, фармакокинетики и лекарственных взаимодействий применения препарата элсульфавирин у здоровых добровольцев и пациентов с нарушением функции печени А.В. Кравченко1, Р.Ю. Арсиенко2, В.Н. Азарова3, А.В. Покровская1, У.А. Куимова1, Е.В. Якубова Инфекционные болезни, 2020, т. 18, N 2, с. 40 - 46

138. Покровский В.В., Юрин О.Г., Кравченко А.В., Беляева В.В., Буравцова В.В., Деулина М.О., Ермак Т.Н., Ефремова О.С., Канестри В.Г., Козырина Н.В., Ладная Н.Н., Нарсия Р.С., Шахгильдян В.И., Куимова У.А., Покровская А.В., Попова А.А., Хохлова О.Н., Воронин Е.Е., Афонина Л.Ю., Зимина В.Н. Рекомендации по лечению ВИЧ-инфекции и связанных с ней заболеваний, химиопрофилактике заражения ВИЧ.//Эпидемиология и инфекционные болезни. Актуальные вопросы. - 2019. - N 4. - 87 с.

139. Trottier B. et al. Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, phase IIIb study//Antivir Ther. - 2017. - Т. 22. - N. 4. - С. 295 - 305.

140. Dickinson L. et al. Comprehensive pharmacokinetic, pharmacodynamic and pharmacogenetic evaluation of once-daily efavirenz 400 and 600 mg in treatment-naive HIV-infected patients at 96 weeks: results of the ENCORE1 study//Clinical pharmacokinetics. - 2016. - Т. 55. - N. 7. - С. 861 - 873.

141. Dubrocq G., Rakhmanina N. The pharmacokinetics, pharmacodynamics, and clinical role of fixed dose combination of tenofovir disoproxil fumarate, lamivudine and reduced dose efavirenz (TLE-400) in treating HIV-1 infection //Expert Opinion on Drug Metabolism & Toxicology. - 2018. - Т. 14. - N. 8. - С. 773 - 779.

142. Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015; 385(9987): 2606 - 2615. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25890673.

143. Wohl D, Oka S, Clumeck N, et al. Brief report: a randomized, double-blind comparison of tenofovir alafenamide versus tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine for initial HIV-1 treatment: week 96 results. J Acquir Immune Defic Syndr. 2016; 72(1): 58 - 64. Available at: http://www.ncbi.nlm.nih.gov/pubmed/26829661.

144. Post F. Adverse events: ART and the kidney: alterations in renal function and renal toxicity//Journal of the International AIDS Society. - 2014. - Т. 17. - С. 19513.

145. Cooper R. D. et al. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients//Clinical Infectious Diseases. - 2010. - Т. 51. - N. 5. - С. 496 - 505.

146. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Developed by the panel on clinical practices for treatment of HIV infection convened by the Department of Health and Human Services (DHHS). July 14, 2016. http://www.AIDSinfo.nih.gov/guidelines

147. NAMSAL ANRS Study Group, Kouanfack C, Mpoudi-Etame M, et al. Dolutegravir-based or low-dose efavirenz-based regimen for the treatment of HIV-1. N Engl J Med. 2019; 381(9): 816 - 826. Available at: https://www.ncbi.nlm.nih.gov/pubmed/31339676.

148. Бобкова М.Р. Лекарственная устойчивость ВИЧ. М.: Человек, 2014. 288 с

149. Rutherford G. W. et al. Predicting treatment failure in adults and children on antiretroviral therapy: a systematic review of the performance characteristics of the 2010 WHO immunologic and clinical criteria for virologic failure//Aids. - 2014. - Т. 28.

150. M Dabrowska M., Mikula T., Wiercinska-Drapalo A. The anemia prevalence and the association between complete blood count analysis and renal function parameters in HIV-1-infected patients//Current HIV research. - 2012. - Т. 10. - N. 3. - С. 247 - 251.

151. Gallant J, Lazzarin A, Mills A, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017; 390 (10107): 2063 - 2072. Available at: http://www.ncbi.nlm.nih.gov/pubmed/28867497.

152. Brenner BG, Thomas R, Blanco JL, et al. Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors. J Antimicrob Chemother. Jul 2016;

153. Clay PG, Nag S, Graham CM, Narayanan S. Meta-analysis of studies comparing single and multi-tablet fixed dose combination HIV treatment regimens. Medicine. Oct 2015; 94(42): e1677. Available at https://www.ncbi.nlm.nih.gov/pubmed/26496277.

154. Pialoux G, Marcelin AG, Despiegel N, Espinas C, Cawston H, Finkielsztejn L et al. Cost-effectiveness of dolutegravir in HIV-1 treatment-experienced (TE) patients in France. PLoS One. 2015; 10: e0145885

155. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV-infection. Recommendation for the public health approach. WHO, 2nd edition, 2016. http: //www.who.int/hiv.

156. Cost-effectiveness of single-versus generic multiple-tablet regimens for treatment of HIV-1 infection in the United States/D. E. Sweet, F. L. Altice, C. J. Cohen, B. Vandewalle//PLoS ONE. - 2016. - Vol. 11(1). - 0147821.

157. Влияние назначения лекарств в виде комбинированных препаратов в фиксированных дозах в сравнении с отдельными таблетками на соблюдение режима лечения: Систематический обзор и мета-анализ/A. van Galen Katy, F. Jeannine Nellen, T. Pythia Nieuwkerk//AIDS Research and Treatment. - 2014. - Vol. Article ID 967073. - http://dx.doi.org/10.1155/2014/967073.

158. Мета-анализ, сравнивающий исходы лечения на 48-ой нед с приемом антиретровирусных препаратов в одной или нескольких таблетках для лечения людей, живущих с ВИЧ/Patrick G. Clay, Wei C. Yuet, Christiane H. Moecklinghoff et al.//AIDS Research and Treatment. - 2018. - Vol. 15. - P. 17.

159. D'Ascenzo F. et al. A meta-analysis investigating incidence and features of stroke in HIV-infected patients in the highly active antiretroviral therapy era//Journal of Cardiovascular Medicine. - 2015. - Т. 16. - N. 12. - С. 839 - 843.

160. Unsal A. B. et al. Effect of antiretroviral therapy on bone and renal health in young adults infected with HIV in early life//The Journal of Clinical Endocrinology & Metabolism. - 2017. - Т. 102. - N. 8. - С. 2896 - 2904.

161. Boender T. S. et al. Long-term virological outcomes of first-line antiretroviral therapy for HIV-1 in low- and middle-income countries: a systematic review and meta-analysis//Clinical Infectious Diseases. - 2015. - Т. 61. - N. 9. - С. 1453 - 1461.

162. Marzinke, M. A. (2016). Therapeutic Drug Monitoring of Antiretrovirals. Clinical Challenges in Therapeutic Drug Monitoring, 135 - 163. doi:10.1016/b978-0-12-802025-8.00006-4.

163. Achhra A. C. et al. Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis//The Lancet HIV. - 2016. - Т. 3. - N. 8. - С. e351 - e360

164. Langebeek N. et al. Predictors and correlates of adherence to combination antiretroviral therapy (ART) for chronic HIV infection: a meta-analysis//BMC medicine. - 2014. - Т. 12. - N. 1. - С. 1 - 14.

165. Corado K. C., Caplan M. R., Daar E. S. Two-drug regimens for treatment of naive HIV-1 infection and as maintenance therapy//Drug design, development and therapy. - 2018. - Т. 12. - С. 3731.

166. van Wyk J. et al. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose Two-Drug Regimen Versus Continuing a Tenofovir Alafenamide-Based Three-or Four-Drug Regimen for Maintenance of Virologic Suppression in Adults With HIV-1: Phase 3, Ra.

167. Gill P. S. et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi"s sarcoma//Journal of Clinical Oncology. - 1996. - Т. 14. - N. 8. - С. 2353 - 2364.

168. Skiest D. J. et al. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection//Clinical infectious diseases. - 2007. - Т. 44. - N. 4. - С. 607 - 614.

169. Corti M., Palmero D. Mycobacterium avium complex infection in HIV/AIDS patients//Expert review of anti-infective therapy. - 2008. - Т. 6. - N. 3. - С. 351 - 363.

170. Frankel E. N. Chemistry of free radical and singlet oxidation of lipids//Progress in lipid research. - 1984. - Т. 23. - N. 4. - С. 197 - 221.

171. Karakousis P. C., Moore R. D., Chaisson R. E. Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy//The Lancet infectious diseases. - 2004. - Т. 4. - N. 9. - С. 557 - 565.

172. Chaisson R. E. et al. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic: Mycobacterium avium complex disease in patients with HIV infection//Aids. - 1997. - Т. 11. - N. 3. - С. 311 - 317.

173. Benson CA, Williams PL, Currier JS, et al. A prospective, randomized trial examining the efficacy and safety ofclarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacteriumavium complex disease in persons with acquired immunodeficiency syndrome. Clin Infect Dis. Nov 1 2003; 37(9): 1234 - 1243.

174. Moyle G. J., Gill J., Nelson M. Once weekly azithromycin as prophylaxis against recurrence of non-tuberculous mycobacterial infections in HIV-1-positive individuals//Aids. - 1998. - Т. 12. - N. 12. - С. 1555 - 1557.

175. Vidanapathirana J. et al. Mass media interventions for promoting HIV testing//Cochrane Database of Systematic Reviews. - 2005. - N. 3.

176. Meader N. et al. Psychosocial interventions for the reduction of injection and sexual risk behaviour for preventing HIV in drug users//Cochrane Database of Systematic Reviews. - 2008. - N. 2.

177. Herrmann E. S. et al. Contingency management interventions for HIV, tuberculosis, and hepatitis control among individuals with substance use disorders: A systematized review//Journal of substance abuse treatment. - 2017. - Т. 72. - С. 117 - 125.

178. Rotheram-Borus M. J., Cantwell S., Newman P. A. HIV prevention programs with heterosexuals. - 2000.

179. Merson M. H. et al. Effectiveness of HIV prevention interventions in developing countries//Aids. - 2000. - Т. 14. - N. Supplement 2.

180. Neumann M. S. et al. Review and meta-analysis of HIV prevention intervention research for heterosexual adult populations in the United States//Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]. - Centre for Reviews a.

181. Faust L., Yaya S. The effect of HIV educational interventions on HIV-related knowledge, condom use, and HIV incidence in sub-Saharan Africa: a systematic review and meta-analysis//BMC public health. - 2018. - Т. 18. - N. 1. - С. 1254.

182. Evangeli M., Pady K., Wroe A. L. Which psychological factors are related to HIV testing? A quantitative systematic review of global studies//AIDS and Behavior. - 2016. - Т. 20. - N. 4. - С. 880 - 918.

183. Covey J., Rosenthal-Stott H. E. S., Howell S. J. A synthesis of meta-analytic evidence of behavioral interventions to reduce HIV/STIs//Journal of behavioral medicine. - 2016. - Т. 39. - N. 3. - С. 371 - 385.

184. Ruiz-Perez I. et al. The effectiveness of HIV prevention interventions in socioeconomically disadvantaged ethnic minority women: a systematic review and meta-analysis//American journal of public health. - 2017. - Т. 107. - N. 12. - С. e13 - e21.

185. Gause N. K. et al. Meta-analyses of HIV prevention interventions targeting improved partner communication: effects on partner communication and condom use frequency outcomes//Journal of Behavioral Medicine. - 2018. - Т. 41. - N. 4. - С. 423 - 440.

186. Yi S. et al. Awareness and willingness to use HIV pre-exposure prophylaxis among men who have sex with men in low- and middle-income countries: a systematic review and meta-analysis//Journal of the international Aids Society. - 2017. - Т. 20. - N. 1. -.

187. LaCroix J. M. et al. Effectiveness of mass media interventions for HIV prevention, 1986 - 2013: a meta-analysis//JAIDS Journal of Acquired Immune Deficiency Syndromes. - 2014. - Т. 66. - С. S329 - S340.

188. Mize S. J. S. et al. Meta-analysis of the effectiveness of HIV prevention interventions for women//AIDS care. - 2002. - Т. 14. - N. 2. - С. 163 - 180.

189. Marks G. et al. Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs//JAIDS Journal of Acquired Immune Deficiency Syndromes. - 2005. - Т. 39. - N.

190. Scholten M. et al. To prescribe, or not to prescribe: decision making in HIV-1 post-exposure prophylaxis//Hiv Medicine. - 2018. - Т. 19. - N. 9. - С. 645 - 653.

191. Ford, N., Shubber, Z., Calmy, A., Irvine, C., Rapparini, C., Ajose, O., ... Mayer, K. H. (2015). Choice of Antiretroviral Drugs for Postexposure Prophylaxis for Adults and Adolescents: A Systematic Review. Clinical Infectious Diseases, 60 (suppl 3), S170 - S17.

192. Сводное руководство ВОЗ по использованию антиретровирусных препаратов для лечения и профилактики ВИЧ-инфекции 2016 г.

193. Ford N. et al. Adherence to HIV postexposure prophylaxis: a systematic review and meta-analysis//Aids. - 2014. - Т. 28. - N. 18. - С. 2721 - 2727.

194. Ippolito G, Puro V, De Carli G; The Italian Study Group on Occupational Risk of HIV infection. Arch Intern Med. The risk of occupational human immunodeficiency virus infection in health care workers: Italian Multicenter Study. Arch Intern Med. 1993; 153(12.

195. Bell DM. Occupational risk of human immunodeficiency virus infection in healthcare workers: an overview. Am J Med. 1997; 102(5B): 9 - 15.

196. D.T. Kuhar, D.K. Henderson, K.A. Struble, W. Heneine. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. 2013; p. 9 - 11. https://npin.cdc.gov/publication/updated-u.

197. Tarantola A., Abiteboul D., Rachline A. Infection risks following accidental exposure to blood or body fluids in health care workers: a review of pathogens transmitted in published cases//American journal of infection control. - 2006. - Т. 34. - N. 6. -.

198. Bock P. et al. Baseline CD4 count and adherence to antiretroviral therapy: a systematic review and meta-analysis//JAIDS Journal of Acquired Immune Deficiency Syndromes. - 2016. - Т. 73. - N. 5. - С. 514 - 521.

199. Siegfried N., Uthman O. A., Rutherford G. W. Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults//Cochrane Database of Systematic Reviews. - 2010. - N. 3.

200. Horvath T. et al. Interventions for preventing late postnatal mother-to-child transmission of HIV//Cochrane database of systematic reviews. - 2009. - N. 1.

201. Drake A. L. et al. Incident HIV during pregnancy and postpartum and risk of mother-to-child HIV transmission: a systematic review and meta-analysis//PLoS Med. - 2014. - Т. 11. - N. 2. - С. e1001608.

202. DART Trial Team et al. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial//The Lancet. - 2010. - Т. 375. - N. 9709. - С. 123 - 131.

203. Ammassari A. et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection//Journal of acquired immune deficiency syndromes (1999). - 2001. - Т. 28. - N. 5. - С. 445 - 449.

204. Chen R. Y. et al. Complete blood cell count as a surrogate CD4 cell marker for HIV monitoring in resource-limited settings//JAIDS Journal of Acquired Immune Deficiency Syndromes. - 2007. - Т. 44. - N. 5. - С. 525 - 530.

205. Vervoort S. C. J. M. et al. The role of HIV nursing consultants in the care of HIV-infected patients in Dutch hospital outpatient clinics//Patient Education and Counseling. - 2010. - Т. 80. - N. 2. - С. 180 - 184

206. Fellay J. et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study//The Lancet. - 2001. - Т. 358. - N. 9290. - С. 1322 - 1327.

207. Simoni, J. M., Kurth, A. E., Pearson, C. R., Pantalone, D. W., Merrill, J. O., & Frick, P. A. (2006). Self-Report Measures of Antiretroviral Therapy Adherence: A Review with Recommendations for HIV Research and Clinical Management. AIDS and Behavior, 10(3), 227 - 245. doi: 10.1007/s10461-006-9078-6

208. Gravemann S. et al. Low-grade proteinuria is highly prevalent in HIV-positive patients on antiretroviral treatment//Aids. - 2014. - Т. 28. - N. 12. - С. 1783 - 1789.

209. Gupta S. K. et al. Prevalence of proteinuria and the development of chronic kidney disease in HIV-infected patients//Clinical nephrology. - 2004. - Т. 61. - N. 1. - С. 1 - 6.

210. Pathai S. et al. Prevalence of HIV-associated ophthalmic disease among patients enrolling for antiretroviral treatment in India: a cross-sectional study//BMC infectious diseases. - 2009. - Т. 9. - N. 1. - С. 158.

211. Miguez-Burbano M. J. et al. Evaluation of HIV prevention and counseling practices of obstetrician/gynecologists in , Colombia: impact on women"s knowledge and risk practices//AIDS education and prevention. - 2002. - Т. 14. - N. 3 Supplement. - С. 72 - 80.

212. Simpson D. M. et al. HIV neuropathy natural history cohort study: assessment measures and risk factors//Neurology. - 2006. - Т. 66. - N. 11. - С. 1679 - 1687.

213. Bwire R., Nagelkerke N. J. D., Borgdorff M. W. Finding patients eligible for antiretroviral therapy using TB services as entry point for HIV treatment//Tropical Medicine & International Health. - 2006. - Т. 11. - N. 10. - С. 1567 - 1575.

214. McDaniel J. S. et al. An assessment of rates of psychiatric morbidity and functioning in HIV disease//General hospital psychiatry. - 1995. - Т. 17. - N. 5. - С. 346 - 352.

215. Feingold AR, Vermund SH, Burk RD, et al. Cervical cytologic abnormalities and papillomavirus in women infected with human immunodeficiency virus. J Acquir Immune Defic Syndr. 1990; 3(9): 896 - 903.

216. Pellowski J. A. et al. A systematic review and meta-analysis of antiretroviral therapy (ART) adherence interventions for women living with HIV//AIDS and Behavior. - 2019. - Т. 23. - N. 8. - С. 1998 - 2013.

217. Barroso, J., Leblanc, N. M., & Flores, D. (2017). It's Not Just the Pills: A Qualitative Meta-Synthesis of HIV Antiretroviral Adherence Research. Journal of the Association of Nurses in AIDS Care, 28(4), 462 - 478. doi: 10.1016/j.jana.2017.02.007.

218. Shubber Z. et al. Patient-Reported Barriers to Adherence to Antiretroviral Therapy: A Systematic Review and Meta-Analysis//PLoS Med. Public Library of Science, 2016. Vol. 13, N 11.

219. Tucker J. D. et al. Enhancing public health HIV interventions: a qualitative meta-synthesis and systematic review of studies to improve linkage to care, adherence, and retention//EBioMedicine. - 2017. - Т. 17. - С. 163 - 171.

220. Кошевая Е.Г., Цинзерлинг В.А. Вторичные заболевания в танатогенезе при ВИЧ-инфекции ВИЧ-инфекция и иммуносупрессии, 2019 г., Том 11, N 1.

221. Пархоменко Ю.Г., Зюзя Ю.Р., Мазус А.И. Морфологические аспекты ВИЧ-инфекции. М.: Литтерра; 2016: 168: ил.

222. Arevalo JF, Gonzalez C, Capparelli EV, et al. Intravitreous and plasma concentrations of ganciclovir and foscarnet after intravenous therapy in patients with AIDS and cytomegalovirus retinitis. J Infect Dis. Oct 1995; 172(4): 951 - 956.

223. Martin DF, Sierra-Madero J, Walmsley S, et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med. Apr 11 2002; 346(15): 1119 - 1126.

224. Arvin AM. Antiviral therapy for varicella and herpes zoster. Semin Pediatr Infect Dis. 2002; 13(1): 12 - 21

225. Wallace MR, Hooper DG, Pyne JM, Graves SJ, Malone JL. Varicella immunity and clinical disease in HIV-infected adults. South Med J. 1994; 87(1): 74 - 76

226. Prober CG, Kirk LE, Keeney RE. Acyclovir therapy of chickenpox in immunosuppressed children - a collaborative study. J Pediatr. 1982; 101(4): 622 - 625.

227. Bozzette SA, Finkelstein DM, Spector SA, et al. A randomized trial of three antiPneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med. 1995; 332(11): 693 - 699.

228. Schneider MM, Hoepelman AI, Eeftinck Schattenkerk JK, et al. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group. N Engl J Med. 1992; 327(26): 1836 - 1841

229. Black JR, Feinberg J, Murphy RL, et al. Clindamycin and primaquine therapy for mild-to-moderate episodes of Pneumocystis carinii pneumonia in patients with AIDS: AIDS Clinical Trials Group 044. Clin Infect Dis. 1994; 18(6): 905 - 913.

230. Safrin S, Finkelstein DM, Feinberg J, et al. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized, trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. ACTG 108 Study Group. Ann Intern Med. 1996; 124(9): 792 - 802.

231. Hughes W, Leoung G, Kramer F, et al. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med. 1993; 328(21): 1521 - 1527.

232. Torre D, Casari S, Speranza F, et al. Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethaminesulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Italian Collaborative Study Group. Antimicrob Agents Chemother. Jun 1998; 42(6): 1346 - 1349.

233. Beraud G, Pierre-Francois S, Foltzer A, et al. Cotrimoxazole for treatment of cerebral toxoplasmosis: an observational cohort study during 1994 - 2006. Am J Trop Med Hyg. Apr 2009; 80(4): 583 - 587.

234. Podzamczer D, Salazar A, Jimenez J, et al. Intermittent trimethoprim-sulfamethoxazole compared with dapsone pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV. Ann Intern Med. May 15 1995; 122(10): 755 - 761.

235. Opravil M, Hirschel B, Lazzarin A, et al. Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients. Clin Infect Dis. Mar 1995; 20(3): 531 - 541.

236. Cooley T, Henry D, Tonda M, Sun S, O'Connell M, Rackoff W. A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi's sarcoma. The Oncologist. 2007; 12(1): 114 - 123.

237. Cianfrocca M, Lee S, Von Roenn J, et al. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. Cancer. 2010; 116(16): 3969 - 3977.

238. Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016; 62(4): e1 - 50.

239. Vazquez JA. Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infection. HIV AIDS (Auckl). 2010; 2(1): 89 - 101.

240. Vazquez JA, Skiest DJ, Nieto L, et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis. 2006; 42(8): 1179 - 1186.

241. de Wet N, Llanos-Cuentas A, Suleiman J, et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis. 2004; 39(6): 842 - 849.

242. Skiest DJ, Vazquez JA, Anstead GM, et al. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis. 2007; 44(4): 607 - 614.

243. Goldman M, Cloud GA, Wade KD, et al. A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40. Clin Infect Dis. 2005; 41(10): 1473 - 1480.

244. Leenders AC, Reiss P, Portegies P, et al. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS. Oct 1997; 11(12): 1463 - 1471.

245. Hamill RJ, Sobel JD, El-Sadr W, et al. Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, doubleblind clinical trial of efficacy and safety. Clin Infect Dis. Jul 15 2010; 51(2): 225 - 232.

246. Saag MS, Cloud GA, Graybill JR, et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis. Feb 1999; 28(2): 291 - 296.

247. Powderly WG, Saag MS, Cloud GA, et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. N Engl J Med. Mar 19 1992; 326(12): 793 - 798.

248. Перегудова, А.Б. Токсоплазмоз у больных ВИЧ-инфекцией: особенности клиники и диагностики: автореф. дис. ... канд. мед. наук: 14.01.09/Перегудова Алла Борисовна; ФБУН "ЦНИИЭ" Роспотребнадзора. - М., 2013. - 24 с.: ил. - Библиогр.: с. 20 - 22.

249. Wang T.T. et al. A meta-analysis of HIV seroprevalence in pregnant women with syphilis and the impact of syphilis infection on mother-to-child HIV transmission//Zhonghua Yu Fang Yi Xue Za Zhi. Zhonghua Yu Fang Yi Xue Za Zhi, 2016. Vol. 50, N 11. P. 1001 - 1007.

250. Sexually Transmitted Infections Among Individuals Using Preexposure Prophylaxis for the Prevention of HIV Infection: A Systematic Review and Meta-analysis//JAMA Netw. open. NLM (Medline), 2019. Vol. 2, N 12. P. e1917134.

251. Hughes E. et al. Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness: a systematic review and meta-analysis//The Lancet Psychiatry. - 2016. - Т. 3. - N. 1. - С. 40 - 48.

252. Chen J. J. et al. Prevalence of hepatitis B and C in HIV-infected patients: a meta-analysis//Hepatobiliary & Pancreatic Diseases International. - 2011. - Т. 10. - N. 2. - С. 122 - 127.

253. Ford N. et al. Burden of HIV-related cytomegalovirus retinitis in resource-limited settings: a systematic review//Clinical infectious diseases. - 2013. - Т. 57. - N. 9. - С. 1351 - 1361.

254. Ch. Hoffmann, J. K. Rockstroh. HIV 2015/16. www.hivbook.com. 2015 by Medizin Fokus Verlag, Hamburg.

255. Pappas P. G. et al. A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis//Clinical infectious diseases. - 2009. - Т. 48. - N. 12. - С. 1775 - 1783.